Abiraterone or Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Has the Veterans Affairs Corporate Data Warehouse Spoken?
JCO Clinical Cancer Informatics · 2026-07 · 10 (3)
DOI: 10.1200/cci-26-00178 ↗Kurz gefasst
Editorial in der Zeitschrift JCO Clinical Cancer Informatics, 2026-07. Verfasst von Wadih Arap und 2 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Cancer Institute, Newark, NJ. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Rutgers Cancer Institute, Newark, NJ.
- Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ.
- Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ.
- MBrace Therapeutics, San Diego, CA.
ORCID-Profile: Wadih Arap
Zitieren
APA
Arap, W., Pasqualini, R., & Chen, I. (2026). Abiraterone or Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Has the Veterans Affairs Corporate Data Warehouse Spoken?. JCO Clinical Cancer Informatics, 10(3). https://doi.org/10.1200/cci-26-00178
Vancouver
Arap W, Pasqualini R, Chen I. Abiraterone or Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Has the Veterans Affairs Corporate Data Warehouse Spoken?. JCO Clinical Cancer Informatics. 2026;10(3). doi:10.1200/cci-26-00178
BibTeX
@article{Arap2026,
author = {Arap, Wadih and Pasqualini, Renata and Chen, Isan},
title = {Abiraterone or Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Has the Veterans Affairs Corporate Data Warehouse Spoken?},
journal = {JCO Clinical Cancer Informatics},
year = {2026},
volume = {10},
number = {3},
doi = {10.1200/cci-26-00178}
}
EUVIMED